How does metformin affect mitochondria at normal doses and is the damage reversible?

Metformin’s effects on mitochondria primarily involve the inhibition of complex I of the electron transport chain. This action decreases the mitochondrial respiratory capacity and results in a reduction in ATP production, subsequently increasing AMP levels. The increased AMP:ATP ratio activates AMP-activated protein kinase (AMPK), a cellular energy sensor. Through AMPK activation, metformin indirectly influences glucose uptake and utilization, underpinning its efficacy in treating type 2 diabetes by improving insulin sensitivity. The concern about “destroying” mitochondria might be overstated for standard therapeutic dosages used in the treatment of diabetes. While it’s true that metformin can reduce mitochondrial activity, this is generally to a degree that is therapeutic and not damaging, under normal dosing conditions prescribed by physicians. In terms of reversibility, studies suggest that the mitochondrial inhibitory effects of metformin are, in fact, reversible. After withdrawal of the medication, mitochondrial function tends to return to baseline levels. However, the nuances of these effects can vary between individuals, based on factors like kidney function, as impaired renal clearance can increase the drug’s action. For patients taking metformin within prescribed dosages, monitoring kidney function is standard to ensure safety. If there are symptoms or concerns such as fatigue or muscle weakness, these should be discussed with a healthcare provider to consider any necessary adjustments. Keeping regular follow-ups with your healthcare provider is essential to address any adverse effects and to ensure that the treatment remains both safe and effective.